个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Long Non-Coding RNA IGFRIL Couples with PTBP1 to Destabilize IGFBP3 mRNA to Promote the IGF1R-AKT-mTOR Axis and Hepatocellular Carcinoma

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Zhang Jing[1,2] * ; Gao Chengming[1] * ; Li Haibei[1,3] * ; Chen Yuying[1,4] * ; Yang Liting[1,5] * ; Jin Qian[1,6] ; Feng Lan[1] ; Wang Xia[1] ; Liu Xinyi[1] ; Chen Hongxia[1] ; Ye Rong[7] ; Xue Yuanchao[7] ; Wang Huiyun[8] ; Zeng Musheng[8] ; Yang Ming[9] ; Ju Huaiqiang[8] ; Gao Chengzhi[1] ; Zhou Guangming[1] ; Zhang Qi[4] ; Zhang Qian[10,11] ; Qin Geng[1] ; Li Yuanfeng[1] ; Wang Yahui[1] ; Yang Aiqing[1] ; Si Anfeng[12] ; Song Qingfeng[13] ; He Fuchu[14] ; Cao Pengbo[1] ; Zhou Gangqiao[1,2,4,10,15] ;
机构： [1]State Key Laboratory of Medical Proteomics, National Center for Protein Sciences at Beijing, Beijing Institute of Radiation Medicine, Beijing, 100850, China. [2]Institute of Life Science and Green Development, College of Life Sciences, Hebei University, Baoding City, Hebei Province, 071000, China. [3]Department of Environment and Health, Military Medical Sciences Academy, Tianjin, 300132, China. [4]Hengyang Medical School, University of South China, Hengyang City, Hunan Province, 421001, China. [5]Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha City, Hunan Province, 410008, China. [6]Jiangsu Key Laboratory of Biological Cancer Therapy, Xuzhou Medical College, Xuzhou City, Jiangsu Province, 221006, China. [7]Key Laboratory of RNA Biology, Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, China. [8]State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou City, Guangdong Province, 510060&#x200c [9], China. [9]Shandong Provincial Key Laboratory of Precision Oncology, Shandong Cancer Hospital and Institute, Jinan City, Shandong Province, 250117, China. [10]Department of Biomed, Medical College of Guizhou University, Guiyang City, Guizhou Province, 550025, China. [11]Department of Research Laboratory Management, West China Hospital of Sichuan University, Chengdu City, Sichuan Province, 610041, China. [12]Department of Surgical Oncolog, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing City, Jiangsu Province, 210015, China. [13]Department of Invasive Technology, Affiliated Cancer Hospital of Guangxi Medical University, Guangxi Zhuang Autonomous Region, Nanning City, 530012, China. [14]State Key Laboratory of Medical Proteomics, National Center for Protein Sciences at Beijing, Beijing Institute of Lifeomics, Beijing, 102206, China. [15]Collaborative Innovation Center for Personalized Cancer Medicine, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing City, Jiangsu Province, 211166, China.
出处：
DOI： 10.1002/advs.202507676

关键词： hepatocellular carcinoma (HCC) IGF1R-AKT-mTOR signaling IGFBP3 long non-coding RNA IGFRIL PTBP1

摘要：
The incomplete understanding of the IGFR pathway activation mechanism limits its clinical application in hepatocellular carcinoma (HCC). Here, a transcriptome-wide screening is performed and a novel HCC-associated lncRNA, named IGFR-inducing lncRNA (IGFRIL) is identified. IGFRIL is frequently upregulated in HCC tissues and predicts poor clinical outcomes. It is revealed that IGFRIL plays an oncogenic role in the development of HCC. Mechanistically, IGFRIL serves as a scaffold to recruit PTBP1, destabilizing IGFBP3 mRNA and thereby overactivating the IGF1R-AKT-mTOR signaling in HCC cells. Furthermore, it is observed that the inhibitors against IGF1R or mTOR exhibit suppressive effects on patient-derived tumor xenograft tumors with high IGFRIL expression, through simultaneous blocking of the IGF1R-AKT-mTOR signaling pathway. In summary, this study identifies IGFRIL as a novel non-coding activator of the IGF1R pathway, providing a promising new therapeutic target for HCC patients.© 2025 The Author(s). Advanced Science published by Wiley‐VCH GmbH.

基金：
the National Key Research and Development Program of China (No. 2022YFC2504700 and 2017YFA0504301) and the National Natural Science Foundation of China (No. 91440206, 82172707, and 82002573).
语种：
外文
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2025]版：
大类 | 1 区 综合性期刊
小类 | 1 区 化学：综合 1 区 材料科学：综合 1 区 纳米科技
最新[2025]版：
大类 | 1 区 综合性期刊
小类 | 1 区 化学：综合 1 区 材料科学：综合 1 区 纳米科技
JCR分区：
出版当年[2024]版：
Q1 CHEMISTRY, MULTIDISCIPLINARY Q1 MATERIALS SCIENCE, MULTIDISCIPLINARY Q1 NANOSCIENCE & NANOTECHNOLOGY
最新[2024]版：
Q1 CHEMISTRY, MULTIDISCIPLINARY Q1 MATERIALS SCIENCE, MULTIDISCIPLINARY Q1 NANOSCIENCE & NANOTECHNOLOGY

影响因子： 最新[2024版] 最新五年平均 出版当年[2024版] 出版当年五年平均 出版前一年[2024版]

第一作者：
第一作者机构： [1]State Key Laboratory of Medical Proteomics, National Center for Protein Sciences at Beijing, Beijing Institute of Radiation Medicine, Beijing, 100850, China. [2]Institute of Life Science and Green Development, College of Life Sciences, Hebei University, Baoding City, Hebei Province, 071000, China.
共同第一作者：
通讯作者：
通讯机构： [1]State Key Laboratory of Medical Proteomics, National Center for Protein Sciences at Beijing, Beijing Institute of Radiation Medicine, Beijing, 100850, China. [2]Institute of Life Science and Green Development, College of Life Sciences, Hebei University, Baoding City, Hebei Province, 071000, China. [4]Hengyang Medical School, University of South China, Hengyang City, Hunan Province, 421001, China. [10]Department of Biomed, Medical College of Guizhou University, Guiyang City, Guizhou Province, 550025, China. [15]Collaborative Innovation Center for Personalized Cancer Medicine, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing City, Jiangsu Province, 211166, China.
推荐引用方式(GB/T 7714)：
Zhang Jing,Gao Chengming,Li Haibei,et al.Long Non-Coding RNA IGFRIL Couples with PTBP1 to Destabilize IGFBP3 mRNA to Promote the IGF1R-AKT-mTOR Axis and Hepatocellular Carcinoma[J].Advanced Science (Weinheim, Baden-Wurttemberg, Germany).2025,e07676.doi:10.1002/advs.202507676.
APA：
Zhang Jing,Gao Chengming,Li Haibei,Chen Yuying,Yang Liting...&Zhou Gangqiao.(2025).Long Non-Coding RNA IGFRIL Couples with PTBP1 to Destabilize IGFBP3 mRNA to Promote the IGF1R-AKT-mTOR Axis and Hepatocellular Carcinoma.Advanced Science (Weinheim, Baden-Wurttemberg, Germany),,
MLA：
Zhang Jing,et al."Long Non-Coding RNA IGFRIL Couples with PTBP1 to Destabilize IGFBP3 mRNA to Promote the IGF1R-AKT-mTOR Axis and Hepatocellular Carcinoma".Advanced Science (Weinheim, Baden-Wurttemberg, Germany) .(2025):e07676

相关文献

[1]Vigilin is overexpressed in hepatocellular carcinoma and is required for HCC cell proliferation and tumor growth. [2]Tenascin-C expression is associated with poor prognosis in hepatocellular carcinoma (HCC) patients and the inflammatory cytokine TNF-α-induced TNC expression promotes migration in HCC cells. [3][MIG7 Regulates the Vasculogenic Mimicry Formation in Hepatocellular Carcinoma then Effects the Metastasis Potential of HCC]. [4]A phase II study of ABSK-011 plus atezolizumab in patients with advanced hepatocellular carcinoma (HCC) [5]Clinical practice status of the adjuvant therapy in hepatocellular carcinoma (HCC): A survey of Chinese hepatobiliary surgeons [6]MIG7调节肝细胞癌中血管生成拟态的形成及其对肝癌转移潜能的影响 [7]Hepatocellular carcinoma (HCC): the most promising therapeutic targets in the preclinical arena based on tumor biology characteristics. [8]Myofibroblast-derived extracellular vesicles facilitate cancer stemness of hepatocellular carcinoma via transferring ITGA5 to tumor cells [9]A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC) [10]The CD39 positive hepatitis B virus surface protein (HBVs)-targeted CAR-T and personalized tumor-reactive CD8+ T cells exhibit potent anti-hepatocellular carcinoma (HCC) activity.

资源点击量：65780 今日访问量：3 总访问量：5151 更新日期：2025-12-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号